Varun Mehta

Senior Director
10+ years of experience in healthcare and life sciences
Expertise in commercial and operational due diligence, go-to-market strategy, revenue acceleration, and commercial excellence programs
Advises multinational corporations on strategic initiatives focused on growth and expansion
Mumbai
@alvarezmarsal
Copied!
Varun Mehta is a Senior Director with Alvarez & Marsal Business Transformation Services in Mumbai. His expertise spans commercial and operational due diligence, go-to-market strategy design and execution, revenue acceleration, and commercial excellence programs.

Mr. Mehta has over a decade of experience advising healthcare and life sciences organizations on strategic and operational initiatives and multinational corporations on a range of strategic initiatives focused on growth and expansion. His notable assignments include designing and implementing a commercial acceleration program for a large pharmaceutical company’s digital therapeutics (DTx) product and developing a market entry strategy for a large Indian conglomerate to establish a presence in multi-specialty hospitals across India.

Mr. Mehta has conducted over 10 commercial due diligence engagements across multi-specialty and single-specialty hospitals and medtech companies in India, Sri Lanka, and Southeast Asia. These evaluations involved assessing market attractiveness, company’s right to win, future profitability and returns outlook, and the operational capabilities required to deliver targeted returns.

Prior to joining A&M, Mr. Mehta spent over five years with Universal Consulting, a boutique management consulting firm. His primary focus was developing growth and go-to-market strategies and route-to-market and pricing strategies for multinational corporations.

Mr. Mehta earned a bachelor’s degree from Narsee Monjee College of Commerce and Economics. He is a qualified Chartered Accountant and a Chartered Financial Analyst (USA) charterholder.

Latest insights The latest insights from Varun Mehta's team
Thought Leadership
Das Transaktions-Volumen der Private-Equity-Branche hat sich 2025 erholt und könnte auch 2026 weiter steigen. Aber nicht um jeden Preis. Entscheidend sind operative Exzellenz und holistische Pläne, die Kapital zu den Investoren zurückbringen. Mehr erfahren.